Ensysce Biosciences (ENSC) shares plummeted 30% on Thursday after the company announced a $5 million registered direct offering and concurrent private placement. The move involved issuing shares at a discounted price, raising concerns among investors. The company plans to use the funds to advance its drug development programs.